The medical device technology firm Surmodics is now a privately held company, following the finalization of its acquisition. A subsidiary of the private equity firm GTCR has successfully taken over the business in a transaction valued at approximately $627 million.
- Acquiring Entity: A subsidiary of GTCR
- Transaction Close: November 19, 2025
- Shareholder Payout: $43.00 per share in cash
- Market Status: Delisted from the Nasdaq exchange
Legal Challenges Overcome to Finalize Deal
The path to privatization involved significant regulatory scrutiny. The U.S. Federal Trade Commission (FTC) initially opposed the merger, seeking a court order to block it. However, a U.S. district court denied the FTC’s request in November 2025, clearing a decisive legal hurdle for the deal to proceed.
Subsequently, the FTC opted not to appeal the court’s decision. This removed the final regulatory obstacles for the transaction, which was first announced in May 2024. For Surmodics shareholders, the outcome was the conversion of their equity into a cash payment of $43.00 for each share held.
Should investors sell immediately? Or is it worth buying Surmodics?
A New Chapter Away from Public Markets
With its delisting from Nasdaq, Surmodics concludes its chapter as a publicly traded entity. All mandatory public reporting obligations have ceased. The company’s strategic direction is now wholly under the control of GTCR.
Operating outside the glare of public markets and without the pressure of quarterly earnings reports, the new ownership can focus on advancing Surmodics’ portfolio of coating technologies and diagnostic components. Future updates on business performance will no longer be disseminated through stock exchange channels but will instead be communicated via private means.
Ad
Surmodics Stock: Buy or Sell?! New Surmodics Analysis from February 7 delivers the answer:
The latest Surmodics figures speak for themselves: Urgent action needed for Surmodics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Surmodics: Buy or sell? Read more here...
